![Ted Xutian Jing](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Ted Xutian Jing
Directeur/Membre du Conseil chez Hopewell Therapeutics, Inc.
Postes actifs de Ted Xutian Jing
Sociétés | Poste | Début | Fin |
---|---|---|---|
Hopewell Therapeutics, Inc.
![]() Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022. | Directeur/Membre du Conseil | - | - |
Historique de carrière de Ted Xutian Jing
Statistiques
Internationale
Etats-Unis | 2 |
Opérationnelle
Director/Board Member | 1 |
Sectorielle
Health Technology | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Entreprise privées | 1 |
---|---|
Hopewell Therapeutics, Inc.
![]() Hopewell Therapeutics, Inc. BiotechnologyHealth Technology Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022. | Health Technology |
- Bourse
- Insiders
- Ted Xutian Jing
- Expérience